Published in Health Business Week, March 26th, 2004
For the quarter ended December 31, 2003, the company reported a net loss of $53.0 million or $0.60 per share, compared to a net loss of $38.9 million or $0.44 per share for the same period in 2002. Fourth quarter 2003 expenses included $9.3 million in costs related to starting up the company's antibody production facilities. The net loss for the fourth quarter of 2003 and 2002 included a $7.9 million and $2.2 million charge, respectively, associated with investments made in connection with collaborations.
Contract revenues for the fourth...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.